Guardant Health Inc. Common Stock 10-K filed 2026-02-19
U.S. Securities and Exchange Commission·2026-02-19·0001576280-26-000013
In the case of an alternative supplier for Illumina, for example, there can be no assurance that replacement sequencers and various associated reagents will be available or will meet our quality control and performance requirements for our laboratory operations.
B · 单方官方披露方向已确认